Literature DB >> 17855433

CXCL16 is a novel mediator of the innate immunity of epidermal keratinocytes.

Mikiko Tohyama1, Koji Sayama, Hitoshi Komatsuzawa, Yasushi Hanakawa, Yuji Shirakata, Xjuju Dai, Lujun Yang, Sho Tokumaru, Hiroshi Nagai, Satoshi Hirakawa, Motoyuki Sugai, Koji Hashimoto.   

Abstract

The epidermis is constantly exposed to a variety of microbial pathogens and plays a vital role in resisting them. Soluble CXC chemokine ligand (CXCL) 16, which is one of the ELR- CXC chemokines, acts as a mediator of innate immunity by attracting CXC chemokine receptor (CXCR) 6-expressing cells, such as activated T cells and NKT cells. However, the production of CXCL16 by non-immune cells remains unclear. We found that cultured keratinocytes produced a significant amount of CXCL16 (2-3 ng per 10(6) cells per 24 h). Stimulation with tumor necrosis factor alpha, IL-1alpha, IFN-gamma, peptidoglycan and polyinosinic-polycytidylic acid [poly(I:C)] enhanced CXCL16 production. The forms of CXCL16 in the culture supernatants had molecular weights of 14, 28 and 50 kDa. Immunohistochemical analysis revealed that the normal human epidermis expressed CXCL16. As several chemokines have anti-microbial activities, we studied the anti-microbial activity of CXCL16. The chemokine domain of CXCL16 at concentrations >5 microg ml(-1) had significant anti-microbial activity against Staphylococcus aureus and Escherichia coli. Killing activity was retained at the physiological salt concentration in the presence of carbonate. In conclusion, CXCL16 is a novel mediator of the innate immune reactivities of epidermal keratinocytes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17855433     DOI: 10.1093/intimm/dxm083

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  25 in total

1.  Early induction of NRF2 antioxidant pathway by RHBDF2 mediates rapid cutaneous wound healing.

Authors:  Vishnu Hosur; Lisa M Burzenski; Timothy M Stearns; Michelle L Farley; John P Sundberg; Michael V Wiles; Leonard D Shultz
Journal:  Exp Mol Pathol       Date:  2017-03-06       Impact factor: 3.362

2.  NKT cells inhibit the development of experimental crescentic glomerulonephritis.

Authors:  Seung Hee Yang; Su Jin Kim; Nakkyung Kim; Ji Eun Oh; Jung Gil Lee; Nam Hyun Chung; Suhnggwon Kim; Yon Su Kim
Journal:  J Am Soc Nephrol       Date:  2008-06-04       Impact factor: 10.121

Review 3.  T-cell positioning by chemokines in autoimmune skin diseases.

Authors:  Jillian M Richmond; James P Strassner; Kingsley I Essien; John E Harris
Journal:  Immunol Rev       Date:  2019-05       Impact factor: 12.988

4.  Innate immune response to influenza A virus in differentiated human alveolar type II cells.

Authors:  Jieru Wang; Mrinalini P Nikrad; Tzulip Phang; Bifeng Gao; Taylor Alford; Yoko Ito; Karen Edeen; Emily A Travanty; Beata Kosmider; Kevan Hartshorn; Robert J Mason
Journal:  Am J Respir Cell Mol Biol       Date:  2011-01-14       Impact factor: 6.914

5.  Ginsenoside Rg5:Rk1 attenuates TNF-α/IFN-γ-induced production of thymus- and activation-regulated chemokine (TARC/CCL17) and LPS-induced NO production via downregulation of NF-κB/p38 MAPK/STAT1 signaling in human keratinocytes and macrophages.

Authors:  Sungeun Ahn; Muhammad Hanif Siddiqi; Veronica Castro Aceituno; Shakina Yesmin Simu; Jinglou Zhang; Zuly Elizabeth Jimenez Perez; Yu-Jin Kim; Deok-Chun Yang
Journal:  In Vitro Cell Dev Biol Anim       Date:  2015-12-29       Impact factor: 2.416

6.  Overexpression of CXCL16 in lesional psoriatic skin.

Authors:  Shin-Taek Oh; Anja Schramme; Wolfgang Tilgen; Paul Gutwein; Jörg Reichrath
Journal:  Dermatoendocrinol       Date:  2009-03

7.  Optimizing the time of Doxil injection to increase the drug retention in transplanted murine mammary tumors.

Authors:  Shaojin You; Lian Zuo; Wei Li
Journal:  Int J Nanomedicine       Date:  2010-04-07

8.  Elevated levels of serum sCXCL16 in systemic lupus erythematosus; potential involvement in cutaneous and renal manifestations.

Authors:  Muting Qin; Yun Guo; Li Jiang; Xiaofei Wang
Journal:  Clin Rheumatol       Date:  2014-07-13       Impact factor: 2.980

9.  Antimicrobial chemokines.

Authors:  Sunny C Yung; Philip M Murphy
Journal:  Front Immunol       Date:  2012-09-11       Impact factor: 7.561

10.  Scavenger receptors and their potential as therapeutic targets in the treatment of cardiovascular disease.

Authors:  Sam L Stephen; Katie Freestone; Sarah Dunn; Michael W Twigg; Shervanthi Homer-Vanniasinkam; John H Walker; Stephen B Wheatcroft; Sreenivasan Ponnambalam
Journal:  Int J Hypertens       Date:  2010-08-17       Impact factor: 2.420

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.